Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | GALR3 | O60755 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11013921 | 0.85 | KDM4C (0.54) | KDM4CAURKARPS6KB1ALDH1A1MAP4K4 | |
| SCHEMBL783719 | 0.81 | KDM4C (0.72) | KDM4CLMNAHTTKDM4EALDH1A1 | |
| SCHEMBL30983851 | 0.81 | KDM4C (0.72) | KDM4CLMNAHTTKDM4EALDH1A1 | |
| SCHEMBL23162568 | 0.78 | LMNA (0.52) | LMNAHTTALOX15AURKARPS6KB1 | |
| SCHEMBL29623213 | 0.78 | LMNA (0.52) | LMNAHTTALOX15AURKARPS6KB1 | |
| SCHEMBL10874371 | 0.78 | KDM4C (0.59) | KDM4CLMNAHTTAURKARPS6KB1 | |
| SCHEMBL4924562 | 0.76 | MAPT (0.52) | LMNAHTTALOX15AURKARPS6KB1 | |
| SCHEMBL30983943 | 0.76 | MAPT (0.52) | LMNAHTTALOX15AURKARPS6KB1 | |
| SCHEMBL1443711 | 0.75 | LMNA (0.66) | LMNAHTTALOX15AURKARPS6KB1 | |
| SCHEMBL17815674 | 0.75 | RAB9A (0.64) | KDM4CLMNAHTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756113-B1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-8236809-B2 | Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation | VASOPHARM GMBH (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | VASOPHARM GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1756113-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | Vasopharm Biotech GmbH (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005111041-A1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM BIOTECH GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
| EP-1598354-A1 | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | Vasopharm Biotech GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | NQO1, CYBB, NADK | KDM4C 3115/4885LMNA 3898/4885HTT 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.